Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Tanba (Boston, United States of America), G. Qi (Boston, United States of America), R. Warburton (Boston, United States of America), K. Penumatsa (Boston, United States of America), D. Toksoz (Boston, United States of America), J. Wilson (Boston, United States of America), H. Farber (Boston, United States of America), N. Hill (Boston, United States of America), I. Preston (Boston, United States of America). Relationship between Galectin-3 and mineralocorticoid receptor in pulmonary hypertension. 1484

Member's Comments

No comment yet.

Related content which might interest you: Endothelin receptor antagonists in pulmonary arterial hypertension Source: Eur Respir J 2008; 31: 407-415 Year: 2008 Decreased expression of the TGF-beta type I receptor ALK1 in pulmonary arterial hypertension Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007 Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment Source: Eur Respir J 2011; 38: 851-860 Year: 2011 Dual endothelin receptor antagonism: setting standards in PAH Source: Eur Respir Rev 2008; 17: 13-18 Year: 2007 Obesity alters oestrogen metabolism and contributes to pulmonary arterial hypertension Source: Eur Respir J, 53 (6) 1801524; 10.1183/13993003.01524-2018 Year: 2019 Peripheral airway dysfunction persist after endothelin receptor antagonist therapy in patients with idiopathic pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary circulation Year: 2009 Estrogen receptor alpha gene polymorphisms and primary pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 352s Year: 2005 Inhalation of endothelin receptor blockers in pulmonary hypertension Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008 Bosentan therapy for portopulmonary hypertension Source: Eur Respir J 2005; 25: 502-508 Year: 2005 Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension? Source: Eur Respir J, 52 (2) 1801287; 10.1183/13993003.01287-2018 Year: 2018 Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure Source: Eur Respir J 2011; 37: 578-586 Year: 2011 Single centre experience with endothelin receptor blockade in pulmonary hypertension Source: Annual Congress 2004 - Pulmonary hypertension Year: 2004 Treatment of early systemic sclerosis associated pulmonary arterial hypertension with endothelin receptor antagonists improves survival Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007 Effects of AT1 receptor blockade on pulmonary and systemic manifestations in a COPD/emphysema mouse model Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009 Endothelin: setting the scene in PAH Source: Eur Respir Rev 2008; 17: 3-7 Year: 2007 Role of interleukin-1 receptor 1/MyD88 signalling in the development and progression of pulmonary hypertension Source: Eur Respir J 2016; 48: 470-483 Year: 2016 NMDA receptor crosstalk with PDGFR-β and BMPR2 is involved in smooth muscle cell proliferation in pulmonary arterial hypertension Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Endothelin-a receptor antagonists reduce eNOS gene expression in rats with chronic hypoxic pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 271s Year: 2003 NMDA receptor activation promotes vascular remodeling and pulmonary arterial hypertension Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018 Role of Gremlin in pulmonary hypertension Source: Annual Congress 2012 - Contributing factors to pulmonary hypertension Year: 2012